The treatment of adult patients with carcinoma of cells basal (most common type of skin cancer ) is renewed with Erivedge , a new medication authorized by the United States Food and Drug Administration (FDA, for its acronym in English).
Erivedge is focused for use in patients with Cancer of cells baseline locally advanced, in those who are not candidates for surgery or radiotherapy , and in those who suffer from metastasis .
The pill, marketed by Genentech, is taken once a day and works by inhibiting the pathway Hedgehog, which is active in most of the cells basal cancer cells, and only in a few normal tissues, such as Hair follicles .
The safety and efficacy of Erivedge It was evaluated in 96 patients with carcinoma of locally advanced or metastatic basal cells. The main objective of the clinical study was the objective response rate (ORR) or the percentage of patients that experienced a total or partial decrease in the injuries cancerous after treatment.
The most common side effects observed in patients treated with the medication were spasms muscle, loss of hair , waste of weight , sickness , diarrhea , sensation of fatigue loss of appetite constipation , vomiting and loss or distortion of the sense of taste in the language.
Further, Erivedge It is approved with a warning box that alerts patients and health professionals of the possible risks of death or serious effects for the fetus , so a possibility of pregnancy It must be checked before starting the treatment.
In the next video of the price of the beauty , the Dermatologist Harry Hidalgo explains what is the skin cancer , its types and some recommendations to prevent it:
According to the specialists, the Basal cell carcinoma it is, generally, of slow growth and without pain; begins to develop in the upper layer of the skin (epidermis), especially in those areas that are regularly exposed to sunlight or ultraviolet radiation.
Follow us at @GetQoralHealth and GetQoralHealth on Facebook
Would you like to receive more information about your interest? Sign up with us